---
run_id: halo-evidence-vs-diagnosis-validation-v8-substrate-workflow-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: substrate_workflow
run_number: 1
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 103
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
condition_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
output_file: model-outputs/substrate_workflow.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `substrate_workflow`, run 1 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 103, on the frozen condition packet.

## Output

I recommend that you advise the CEO to **run the targeted evidence pass** (Option 2).

### Reasoning
The current "upbeat story" presented for the board packet is a textbook instance of the **Halo Effect** (BK-0048-card-001). The shift in leadership’s perception—moving from describing the team as "too bespoke and reactive" to "customer-obsessed and disciplined"—coincides exactly with a bump in revenue. Per BK-0048, these trait assessments are not independent evidence of improved discipline; they are reflections of the performance signal. Because the revenue bump is largely artificial (driven by discounts and early-renewal incentives), the "halo" is masking a lack of fundamental product-market fit.

Furthermore, the company is currently confusing "execution" with "progress." According to the principle of **Validated Learning** (BK-0007-card-001), real progress is not measured by shipping features or hitting revenue targets—especially when those targets are inflated by discounts—but by empirical evidence of customer behavior. The current data shows a critical failure in validated learning:
1. **Front-line abandonment:** Only 31% of reviewers return after the first week.
2. **Theatricality:** Positive quotes were collected after customers were told the feature was a top priority, and product issues are being reclassified as "training questions" to protect the narrative.
3. **Structural Blockers:** In the regulated insurance segment, the product is unusable because it fails the "auditor explainability" test.

To commit to scaling (Option 1) or pivoting (Option 3) right now would be to build a strategy without a valid **Diagnosis** (BK-0001-card-001). Scaling a product with 31% front-line retention is not a strategy; it is a gamble on a flawed kernel. The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

### The Strongest Reason Against This Recommendation
**Opportunity Cost and Political Risk.** The board locks the budget in twelve days. Pausing discounts and instrumenting behavior takes time and creates a "momentum gap." In a high-pressure B2B environment, the CEO may view a "targeted evidence pass" as a lack of conviction or a failure to seize a market wedge. By choosing to learn rather than scale, you risk the board perceiving the company as hesitant while competitors potentially move faster into the mid-market compliance space.

### Observable Evidence That Would Change My Mind
I would change this recommendation to **Option 3 (Narrow to Regulated Compliance)** if the evidence pass reveals that the "compliance operations champions" (the small group driving the 44% usage increase) are not just "rerunning samples," but are using the tool to generate the very auditor-ready documentation that the front-line reviewers are struggling with.

If the "champion" behavior indicates that the product's true value is as a *supervisory/audit-prep tool* rather than a *triage tool*, the diagnosis changes fundamentally. In that case, the "auditor explainability" problem is no longer a bug to be fixed, but the core value proposition of the product, justifying an immediate strategic pivot.
